Literature DB >> 31765597

Airway Mucus Hyperconcentration in Non-Cystic Fibrosis Bronchiectasis.

Kathryn A Ramsey1,2, Alice C H Chen3,4, Giorgia Radicioni1, Rohan Lourie3,5, Megan Martin6, Amy Broomfield5, Yong H Sheng3, Sumaira Z Hasnain3, Graham Radford-Smith7, Lisa A Simms8, Lucy Burr3,6, David J Thornton9, Simon D Bowler6, Stephanie Livengood1, Agathe Ceppe1, Michael R Knowles1, Peadar G Noone1, Scott H Donaldson1, David B Hill1,10, Camille Ehre1, Brian Button1, Neil E Alexis11, Mehmet Kesimer1, Richard C Boucher1, Michael A McGuckin3,12.   

Abstract

Rationale: Non-cystic fibrosis bronchiectasis is characterized by airway mucus accumulation and sputum production, but the role of mucus concentration in the pathogenesis of these abnormalities has not been characterized.
Objectives: This study was designed to: 1) measure mucus concentration and biophysical properties of bronchiectasis mucus; 2) identify the secreted mucins contained in bronchiectasis mucus; 3) relate mucus properties to airway epithelial mucin RNA/protein expression; and 4) explore relationships between mucus hyperconcentration and disease severity.
Methods: Sputum samples were collected from subjects with bronchiectasis, with and without chronic erythromycin administration, and healthy control subjects. Sputum percent solid concentrations, total and individual mucin concentrations, osmotic pressures, rheological properties, and inflammatory mediators were measured. Intracellular mucins were measured in endobronchial biopsies by immunohistochemistry and gene expression. MUC5B (mucin 5B) polymorphisms were identified by quantitative PCR. In a replication bronchiectasis cohort, spontaneously expectorated and hypertonic saline-induced sputa were collected, and mucus/mucin concentrations were measured.Measurements and Main
Results: Bronchiectasis sputum exhibited increased percent solids, total and individual (MUC5B and MUC5AC) mucin concentrations, osmotic pressure, and elastic and viscous moduli compared with healthy sputum. Within subjects with bronchiectasis, sputum percent solids correlated inversely with FEV1 and positively with bronchiectasis extent, as measured by high-resolution computed tomography, and inflammatory mediators. No difference was detected in MUC5B rs35705950 SNP allele frequency between bronchiectasis and healthy individuals. Hypertonic saline inhalation acutely reduced non-cystic fibrosis bronchiectasis mucus concentration by 5%.Conclusions: Hyperconcentrated airway mucus is characteristic of subjects with bronchiectasis, likely contributes to disease pathophysiology, and may be a target for pharmacotherapy.

Entities:  

Keywords:  gene expression; induced sputum; mucin

Mesh:

Substances:

Year:  2020        PMID: 31765597      PMCID: PMC7068838          DOI: 10.1164/rccm.201906-1219OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  35 in total

1.  A study of the pathology and pathogenesis of bronchiectasis.

Authors:  F WHITWELL
Journal:  Thorax       Date:  1952-09       Impact factor: 9.139

2.  Coordinated release of nucleotides and mucin from human airway epithelial Calu-3 cells.

Authors:  Silvia M Kreda; Seiko F Okada; Catharina A van Heusden; Wanda O'Neal; Sherif Gabriel; Lubna Abdullah; C William Davis; Richard C Boucher; Eduardo R Lazarowski
Journal:  J Physiol       Date:  2007-07-26       Impact factor: 5.182

3.  Secreted mucins and airway bacterial colonization in non-CF bronchiectasis.

Authors:  Oriol Sibila; Guillermo Suarez-Cuartin; Ana Rodrigo-Troyano; Thomas C Fardon; Simon Finch; Eder Freddy Mateus; Laia Garcia-Bellmunt; Diego Castillo; Silvia Vidal; Ferran Sanchez-Reus; Marcos I Restrepo; James D Chalmers
Journal:  Respirology       Date:  2015-07-14       Impact factor: 6.424

4.  Receptor-promoted exocytosis of airway epithelial mucin granules containing a spectrum of adenine nucleotides.

Authors:  Silvia M Kreda; Lucia Seminario-Vidal; Catharina A van Heusden; Wanda O'Neal; Lisa Jones; Richard C Boucher; Eduardo R Lazarowski
Journal:  J Physiol       Date:  2010-04-26       Impact factor: 5.182

5.  Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.

Authors:  Thierry Bienvenu; Isabelle Sermet-Gaudelus; Pierre-Regis Burgel; Dominique Hubert; Bruno Crestani; Laurence Bassinet; Daniel Dusser; Isabelle Fajac
Journal:  Am J Respir Crit Care Med       Date:  2010-02-18       Impact factor: 21.405

6.  Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.

Authors:  David J Serisier; Megan L Martin; Michael A McGuckin; Rohan Lourie; Alice C Chen; Barbara Brain; Sally Biga; Sanmarié Schlebusch; Peter Dash; Simon D Bowler
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

7.  Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure.

Authors:  Ashley G Henderson; Camille Ehre; Brian Button; Lubna H Abdullah; Li-Heng Cai; Margaret W Leigh; Genevieve C DeMaria; Hiro Matsui; Scott H Donaldson; C William Davis; John K Sheehan; Richard C Boucher; Mehmet Kesimer
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

8.  MUC5B promoter polymorphism and interstitial lung abnormalities.

Authors:  Gary M Hunninghake; Hiroto Hatabu; Yuka Okajima; Wei Gao; Josée Dupuis; Jeanne C Latourelle; Mizuki Nishino; Tetsuro Araki; Oscar E Zazueta; Sila Kurugol; James C Ross; Raúl San José Estépar; Elissa Murphy; Mark P Steele; James E Loyd; Marvin I Schwarz; Tasha E Fingerlin; Ivan O Rosas; George R Washko; George T O'Connor; David A Schwartz
Journal:  N Engl J Med       Date:  2013-05-21       Impact factor: 91.245

9.  Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH.

Authors:  David B Hill; Robert F Long; William J Kissner; Eyad Atieh; Ian C Garbarine; Matthew R Markovetz; Nicholas C Fontana; Matthew Christy; Mehdi Habibpour; Robert Tarran; M Gregory Forest; Richard C Boucher; Brian Button
Journal:  Eur Respir J       Date:  2018-12-06       Impact factor: 16.671

10.  Adult non-cystic fibrosis bronchiectasis is characterised by airway luminal Th17 pathway activation.

Authors:  Alice C-H Chen; Megan L Martin; Rohan Lourie; Geraint B Rogers; Lucy D Burr; Sumaira Z Hasnain; Simon D Bowler; Michael A McGuckin; David J Serisier
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

View more
  21 in total

1.  Assembly and organization of the N-terminal region of mucin MUC5AC: Indications for structural and functional distinction from MUC5B.

Authors:  Jerome Carpenter; Yang Wang; Richa Gupta; Yuanli Li; Prashamsha Haridass; Durai B Subramani; Boris Reidel; Lisa Morton; Caroline Ridley; Wanda K O'Neal; Marie-Pierre Buisine; Camille Ehre; David J Thornton; Mehmet Kesimer
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-28       Impact factor: 11.205

2.  Cystic Fibrosis Airway Mucus Hyperconcentration Produces a Vicious Cycle of Mucin, Pathogen, and Inflammatory Interactions that Promotes Disease Persistence.

Authors:  Bethany D Batson; Bryan T Zorn; Giorgia Radicioni; Stephanie S Livengood; Tadahiro Kumagai; Hong Dang; Agathe Ceppe; Phillip W Clapp; Michael Tunney; J Stuart Elborn; Noel G McElvaney; Marianne S Muhlebach; Richard C Boucher; Michael Tiemeyer; Matthew C Wolfgang; Mehmet Kesimer
Journal:  Am J Respir Cell Mol Biol       Date:  2022-08       Impact factor: 7.748

3.  Induction of ciliary orientation by matrix patterning and characterization of mucociliary transport.

Authors:  Patrick R Sears; Ximena M Bustamante-Marin; Henry Gong; Matthew R Markovetz; Richard Superfine; David B Hill; Lawrence E Ostrowski
Journal:  Biophys J       Date:  2021-03-09       Impact factor: 4.033

4.  Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.

Authors:  Giorgia Radicioni; Agathe Ceppe; Amina A Ford; Neil E Alexis; R Graham Barr; Eugene R Bleecker; Stephanie A Christenson; Christopher B Cooper; MeiLan K Han; Nadia N Hansel; Annette T Hastie; Eric A Hoffman; Richard E Kanner; Fernando J Martinez; Esin Ozkan; Robert Paine; Prescott G Woodruff; Wanda K O'Neal; Richard C Boucher; Mehmet Kesimer
Journal:  Lancet Respir Med       Date:  2021-05-28       Impact factor: 102.642

Review 5.  Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease.

Authors:  Michael C McKelvey; Ryan Brown; Sinéad Ryan; Marcus A Mall; Sinéad Weldon; Clifford C Taggart
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

6.  Small Airway Disease and Emphysema Are Associated with Future Exacerbations in Smokers with CT-derived Bronchiectasis and COPD: Results from the COPDGene Cohort.

Authors:  Diego Jose Maselli; Andrew Yen; Wei Wang; Yuka Okajima; Wojciech R Dolliver; Christina Mercugliano; Antonio Anzueto; Marcos I Restrepo; Timothy R Aksamit; Ashwin Basavaraj; Stefano Aliberti; Kendra A Young; Gregory L Kinney; J Michael Wells; Raúl San José Estépar; David A Lynch; Alejandro A Diaz
Journal:  Radiology       Date:  2021-06-22       Impact factor: 29.146

7.  "Can't Stop the Feeling": Symptoms as the Key to Trial Success in Bronchiectasis?

Authors:  Pierre-Régis Burgel; Sanjay H Chotirmall
Journal:  Am J Respir Crit Care Med       Date:  2020-06-15       Impact factor: 21.405

8.  Happy Birthday, Bronchiectasis: 200 Years of Targeting Mucus.

Authors:  James D Chalmers; Oriol Sibila
Journal:  Am J Respir Crit Care Med       Date:  2020-03-15       Impact factor: 21.405

Review 9.  The Potential Role and Regulatory Mechanisms of MUC5AC in Chronic Obstructive Pulmonary Disease.

Authors:  Jingyuan Li; Zuguang Ye
Journal:  Molecules       Date:  2020-09-27       Impact factor: 4.411

Review 10.  ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies.

Authors:  Marcus A Mall
Journal:  Eur Respir J       Date:  2020-12-24       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.